These data demonstrate significant antitumor activity with exoASO-STAT6 therapy in the Hepa1-6 orthotopic tumor model and a lack of systemic inflammation by intravenous dosing of exoASO-STAT6. This evidence concerns the gene STAT6 and neoplasm.